Drug–drug interactions in targeted cancer therapies: a focus on tyrosine kinase inhibitors
Jack C Stromatt, Anika T Chowdhury, Kevin M Huang, Shuiying Hu, Alex Sparreboom, Sharyn D Baker, Eric D Eisenmann · 2025
Read Drug–drug interactions in targeted cancer therapies: a focus on tyrosine kinase inhibitors by Jack C Stromatt, Anika T Chowdhury, Kevin M Huang, Shuiying Hu, Alex Sparreboom, Sharyn D Baker, Eric D Eisenmann (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12834180.txt.
Description
Tyrosine kinase inhibitors have changed cancer care, but they are often taken alongside many other drugs, and the combinations can backfire. The authors review how these interactions happen, drawing on a drug interaction database, official drug labels, and the published literature. They separate two families of interaction. One family changes how a drug is absorbed, spread, broken down, and cleared. In the other, two drugs' effects add up, clash, or multiply at the same target.
Interactions of the first kind can arise through direct blocking, chemical modification of enzymes, or changes in gene activity. Either family can push a patient toward toxicity or leave the cancer drug too weak to work. The authors argue that knowing the mechanism behind an interaction helps clinicians adjust doses in advance rather than react to harm. They frame the review as groundwork for safer dosing strategies in patients on these therapies.
Catalog record
| CREATOR | Jack C Stromatt, Anika T Chowdhury, Kevin M Huang, Shuiying Hu, Alex Sparreboom, Sharyn D Baker, Eric D Eisenmann |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 58 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |